Fibrobiologics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd report acquiring a 9.99% beneficial ownership in FibroBiologics, Inc. common stock.
NASDAQ
Lind Global Fund III LP, along with affiliated entities and individuals, has filed a Schedule 13G, reporting beneficial ownership of 4.99% of FibroBiologics, Inc. common stock.
NASDAQ
SCHEDULE 13G/A: BlackRock, Inc. Discloses 2.0% Stake in FibroBiologics, Inc.
BlackRock, Inc. filed an Amendment No. 2 to Schedule 13G, reporting a 2.0% beneficial ownership stake in FibroBiologics, Inc. as of June 30, 2025.
NASDAQ
Mike Newlin has filed a Schedule 13G, disclosing beneficial ownership of 2,134,853 shares, representing 5.579% of FibroBiologics, Inc.'s common stock.
NASDAQ
Pete O'Heeron, a key figure at FibroBiologics, Inc., has disclosed a beneficial ownership of 18.2% of the company's common stock as of January 31, 2024, through a Schedule 13G filing.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in FibroBiologics, Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.1% Stake in FibroBiologics, Inc.
Global asset manager BlackRock, Inc. has reported a 5.1% beneficial ownership stake in FibroBiologics, Inc. as of December 31, 2024, according to a recent Schedule 13G filing.